References
- 1. Flores B, Trivedi HD, Robson SC, Bonder A. Hemostasis, bleeding and thrombosis in liver disease. Journal of translational science. 2017;3(3).10.15761/JTS.1000182613643530221012
- 2. Buresi M, Hull R, Coffin CS. Venous thromboembolism in cirrhosis: a review of the literature. Canadian Journal of Gastroenterology and Hepatology. 2012;26(12):9058.10.1155/2012/175849
- 3. Dhar A, Mullish BH, Thursz MR. Anticoagulation in chronic liver disease. Journal of hepatology. 2017;66(6):131326.10.1016/j.jhep.2017.01.00628088580
- 4. Stine JG, Intagliata NM, Shah NL, Lisman T, Violi F, Caldwell SH, et al. Clinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease Conference. Digestive Diseases and Sciences. 2019;16.10.1007/s10620-019-05884-0716002431628574
- 5. Villa and E, De Maria N. Anticoagulation in cirrhosis. Liver international. 2012;32(6):8789.10.1111/j.1478-3231.2012.02825.x
- 6. Rank KM, Lake J. COn: anticoagulation for Portal vein Thrombosis in advanced Cirrhosis. Clinical liver disease. 2018;12(3):80.10.1002/cld.713638591230988916
- 7. Søgaard KK, Horváth-Puhó E, Grønbæk H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based casecontrol study. The American journal of gastroenterology. 2009;104(1):96.10.1038/ajg.2008.3419098856
- 8. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB. 2009;11(6):45964.10.1111/j.1477-2574.2009.00079.x275663119816608
- 9. Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World journal of gastroenterology: WJG. 2014;20(19):5737.10.3748/wjg.v20.i19.5737402478424914335
- 10. Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. In Thieme Medical Publishers; 2019. p. 195208.10.1055/s-0039-167993430978730
- 11. Kalambokis GN, Baltayiannis G, Christodoulou D. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis. World journal of gastroenterology. 2016;22(19):4786.10.3748/wjg.v22.i19.4786487008627217711
- 12. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5): 125360.10.1053/j.gastro.2012.07.01822819864
- 13. To UK, Garcia-Tsao G. PrO: Patients With advanced Cirrhosis and Portal vein Thrombosis should receive anticoagulation. Clinical liver disease. 2018;12(3):74.10.1002/cld.717638591830988915
- 14. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver International. 2014;34(1):2632.10.1111/liv.1221123758818
- 15. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Torres-Ortiz A, O’Corragain OA, Watthanasuntorn K, et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis. Digestive and Liver Disease. 2019;51(4):48995.10.1016/j.dld.2018.12.00130594462
- 16. Dhar A, Sadiq F, Anstee QM, Levene AP, Goldin RD, Thursz MR. Thrombin and factor Xa link the coagulation system with liver fibrosis. BMC gastroenterology. 2018;18(1):60.10.1186/s12876-018-0789-8594165829739329
- 17. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis Possibilities and caveats. Journal of hepatology. 2013;59(2):35866.10.1016/j.jhep.2013.03.02723548197
- 18. Youngwon N, Kim J-E, Lim HS, Han K-S, Kim HK. Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. BioMed research international. 2013;2013.10.1155/2013/856754359510723555099
- 19. Li C-J, Yang Z-H, Shi X-L, Liu D-L. Effects of aspirin and enoxaparin in a rat model of liver fibrosis. World journal of gastroenterology. 2017;23(35):6412.10.3748/wjg.v23.i35.6412564326629085190
- 20. Gallagher C, Sanders P, Wong CX. Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low-Dose Non-Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin? 2019;10.1161/JAHA.119.012102647492730834801
- 21. EASL E. EASO. Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease, Obes Facts. 2016;9:6590.10.1159/000443344